Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 11/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17726457 | 0.92 | GHSR (0.56) | GHSRESR2 | |
| SCHEMBL3993278 | 0.90 | ESR2 (0.44) | GHSRESR2SIGMAR1 | |
| SCHEMBL4481872 | 0.88 | ESR2 (0.49) | GHSRESR2 | |
| SCHEMBL3294838 | 0.84 | ESR2 (0.52) | GHSRESR2 | |
| SCHEMBL3616932 | 0.84 | GHSR (0.48) | GHSR | |
| SCHEMBL3615809 | 0.84 | GHSR (0.46) | GHSR | |
| SCHEMBL7511979 | 0.84 | ESR2 (0.54) | GHSRESR2 | |
| SCHEMBL17726266 | 0.83 | GHSR (0.53) | GHSR | |
| SCHEMBL17726458 | 0.82 | GHSR (0.55) | GHSR | |
| SCHEMBL3599583 | 0.82 | GHSR (0.49) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168075-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168075-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | CYP46A1, NPC1L1, NPC1 | GHSR 2377/4885ESR2 1452/4885TMEM97 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.